SCCA Leukemia Clinical Trials Finder
Click on the headings below to view relevant trials for the condition listed.
Acute Lymphoid Leukemia - (4 trials)
- Intergroup Phase II Trial for Adolescents and Young Adults with Untreated ALL (SWOG C10403)
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (SWOG C10403) - Epratuzumab plus Cytarabine and Clofarabine Relapsed or Refractory ALL (SWOG 0910)
A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Negative Precursor B-cell Acute Lymphoblastic Leukemia (ALL) - Inotuzumab Ozogamicin for Acute Lymphocytic Leukemia (UW11021)
An Open-Label, Phase 1 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory CD22-Positive Acute Lymphocytic Leukemia -
Philadelphia + (1 trial)
- Hyper-CVAD and Dasatinib w/wo Donor STM for ALL (SWOG-0805)
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
- Hyper-CVAD and Dasatinib w/wo Donor STM for ALL (SWOG-0805)
Acute Myeloid Leukemia - Newly Diagnosed (7 trials)
- Chemotherapy Followed Cord Blood Infusion for Patients with AML (FHCRC-2335)
Clofarabine in Combination with Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients with AML - Clofarabine, Cytarabine, and G-CSF for Newly Diagnosed Acute Myeloid Leukemia or Advanced MDS (7144)
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Under Age 60 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome - Plerixafor Combined With Cytarabine and Daunorubicin De Novo AML (UW09011)
A Phase 1, Dose Escalation Study of Plerixafor in combination with Cytarabine and Daunorubicin in Patients with De Novo Acute Myeloid Leukemia - Bendamustine Hydrochloride and Idarubicin for Previously Untreated AML or MDS (2413)
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS) -
PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies Or In Combination With Dasatinib In Chronic Myeloid Leukemia (CML) - PARP Inhibitor BMN 673 for Advanced Hematological Malignancies (UW11003)
Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN 673 in Patients With Advanced Hematological Malignancies - Azacitidine + Gemtuzumab for Previously Untreated AML (SWOG 0703)
A Phase II Trial of Azacitidine plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Older patients with Previously Untreated Non-M3 Acute myeloid Leukemia
Acute Myeloid Leukemia Relapsed or Never in Complete Response - First Salvage (9 trials)
-
AGE < 70 (1 trial)
- Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia
- Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
-
AGE > 50 (1 trial)
- Vorinostat + Gemtuzumab Ozogamicin/Azacitidine for AML (FHCRC-2288)
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML)
- Vorinostat + Gemtuzumab Ozogamicin/Azacitidine for AML (FHCRC-2288)
-
AGE > 60 (1 trial)
- Clofarabine + Cytarabine for Older Patients With AML (FHCRC-2302)
A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age
- Clofarabine + Cytarabine for Older Patients With AML (FHCRC-2302)
-
ANY AGE (6 trials)
- PARP Inhibitor BMN 673 for Advanced Hematological Malignancies (UW11003)
Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN 673 in Patients With Advanced Hematological Malignancies - PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies Or In Combination With Dasatinib In Chronic Myeloid Leukemia (CML) - Cyclosporine Modulation of drug resistance with Pravastatin, Etoposide, and Mitoxantrone for Relapsed or Refractory AML (2409)
Cyclosporine Modulation of Drug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study - Idarubicin, Cytarabine, and Pravastatin for Patients With Relapsed Acute Myeloid Leukemia (SWOG 0919)
A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute myelogenous Leukemia - CWP232291 for Relapsed or Refractory AML (2513)
A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) - PLX3397 for Relapsed or Refractory Acute Myeloid Leukemia (2532)
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- PARP Inhibitor BMN 673 for Advanced Hematological Malignancies (UW11003)
Acute Myeloid Leukemia Relapsed or Never in Complete Response - Second Salvage + (6 trials)
-
2nd Salvage Only
- AKT Kinase Inhibitor MK-2206 For Relapsed Refractory AML (2466)
Phase 2 Study of the AKT Kinase inhibitor MK-2206 in Patients with Relapsed Refractory Acute Myelogenous Leukemia
- AKT Kinase Inhibitor MK-2206 For Relapsed Refractory AML (2466)
-
> 2nd Salvage
- Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia - Cyclosporine Modulation of drug resistance with Pravastatin, Etoposide, and Mitoxantrone for Relapsed or Refractory AML (2409)
Cyclosporine Modulation of Drug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study - PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies Or In Combination With Dasatinib In Chronic Myeloid Leukemia (CML) - PARP Inhibitor BMN 673 for Advanced Hematological Malignancies (UW11003)
Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN 673 in Patients With Advanced Hematological Malignancies - CWP232291 for Relapsed or Refractory AML (2513)
A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
Acute Myeloid Leukemia Complete Response/Remission (1 trial)
- Bortezomib for High-Risk Acute Myeloid Leukemia in Remission (2529)
A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission
Acute Promyeloid Leukemia (APL) (1 trial)
- Gemtuzumab + Combo Chemotherapy for Previously Untreated APL (SWOG 0535)
A Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia
Chronic Lymphoid Leukemia (4 trials)
- DCDS4501A for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (2501)
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia - Bendamustine vs. Bendamustine + TRU-016 for CLL (2441)
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia - Bexxar Consolidation CLL or SLL (PSOC 2301)
A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission - Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)
Chronic Myeloid Leukemia (3 trials)
- PF-04449913 for Hematologic Malignancies (B1371001)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies Or In Combination With Dasatinib In Chronic Myeloid Leukemia (CML) - LBH589 with Imatinib Mesylate for CML (2412)
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR - Ponatinib (AP24534) for Refractory CML & Ph+ ALL (2460)
A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome including CMML (4 trials)
- Treosulfan + Fludarabine + TBI for Allo HCT for AML and MDS (FHCRC-2272)
Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) - Clofarabine + Cytarabine to Treat Minimal Residual Disease (MRD) in AML (UWCC-6858)
A Phase II Trial of Clofarabine and Cytarabine to Treat Minimal Residual Disease (MRD) in Acute Myeloid Leukemia - Bendamustine Hydrochloride and Idarubicin for Previously Untreated AML or MDS (2413)
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS) - Lenalidomide With or Without Epoetin Alfa for Myelodysplastic Syndrome (CTSU E2905)
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Transplant Failures (8 trials)
- Azacitidine +/- Gemtuzumab for Post-Transplant Relapse for MDS, CMML and AML (FHCRC-2240)
Treatment of Post-Transplant Relapse and Persistent Disease in Patients with MDS, CMML and AML with Azacitidine +/- Gemtuzumab - Vorinostat + Gemtuzumab Ozogamicin/Azacitidine for AML (FHCRC-2288)
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML) - Clofarabine + Cytarabine for Older Patients With AML (FHCRC-2302)
A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age - Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia - PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies Or In Combination With Dasatinib In Chronic Myeloid Leukemia (CML) - Cyclosporine Modulation of drug resistance with Pravastatin, Etoposide, and Mitoxantrone for Relapsed or Refractory AML (2409)
Cyclosporine Modulation of Drug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study - CWP232291 for Relapsed or Refractory AML (2513)
A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) - AKT Kinase Inhibitor MK-2206 For Relapsed Refractory AML (2466)
Phase 2 Study of the AKT Kinase inhibitor MK-2206 in Patients with Relapsed Refractory Acute Myelogenous Leukemia
Ancillary Trials (2 trials)
- Early Discharge and Outpatient Care MDS and AML Patients (2449)
Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML - Granulocyte Transfusions for Neutropenia (2311)
High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia: The RING Study (Resolving Infection in Neutropenia With Granulocytes)
Clinical Trial Finder beta 2 updated 6/7/12.